NEW YORK (GenomeWeb) – Meridian Bioscience today reported its first quarter revenues rose 12 percent, with growth in both its life sciences and diagnostics businesses somewhat offset by losses in its Magellan lead testing unit.

For the three months ended Dec. 31, 2017, revenues increased to $52.3 million from $46.8 million a year ago, beating Wall Street analysts' average estimate of $49.0 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.